HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Structure and Functional Characterization of a Humanized Anti-CCL20 Antibody following Exposure to Serum Reveals the Formation of Immune Complex That Leads to Toxicity.

Abstract
mAbs have revolutionized the treatment of autoimmune disorders. Even though mAbs have shown impressive efficacy in blocking T cell or B cell activation and/or recruitment to sites of inflammation, this group of biologicals are not devoid of adverse effects. The most serious adverse effects include infusion reactions, including the activation of the complement pathway. In this study, we present a detailed structure-function study of an anti-CCL20 humanized IgG1 mAb that neutralizes CCL20 chemokine and prevents the recruitment of Th17 cells to sites of inflammation. We demonstrate that the anti-CCL20 Ab changes significantly following administration to humans and monkeys and exposure to human serum. Analysis of the drug product revealed that the anti-CCL20 Ab has unexpectedly high C1q binding. This high binding was linked to immune complex formation in vivo but not during in vitro serum incubation. The immune complex contained multiple complement components. Anti-CCL20 Ab-mediated, complement-dependent cytotoxicity occurred when the Ab bound to CCL20 tethered to the cell membrane of target cells. Taken together, these results provide a likely cause for the animal toxicity observed. In addition, anti-CCL20 revealed progressive acidification because of N100 (located in CDR) deamidation over time, which did not directly impact Ag binding. Our study demonstrates that the safety profiling of mAbs should include the evaluation of effector functions in addition to typical stressed conditions.
AuthorsAndrew S Thomson, Shing H Mai, Gerben Bouma, Michael Herdman, Michael Byrne, Charles S Hottenstein, Joseph Minetti, Stephen Trulli, J David Taylor, John R White, Shugui Chen
JournalJournal of immunology (Baltimore, Md. : 1950) (J Immunol) Vol. 206 Issue 5 Pg. 1067-1076 (03 01 2021) ISSN: 1550-6606 [Electronic] United States
PMID33483346 (Publication Type: Journal Article)
CopyrightCopyright © 2021 by The American Association of Immunologists, Inc.
Chemical References
  • Antibodies, Monoclonal
  • Antigen-Antibody Complex
  • CCL20 protein, human
  • Chemokine CCL20
  • Immunoglobulin G
  • Complement System Proteins
Topics
  • Animals
  • Antibodies, Monoclonal (immunology)
  • Antigen-Antibody Complex (immunology)
  • Autoimmune Diseases (immunology)
  • Cell Membrane (immunology)
  • Chemokine CCL20 (immunology)
  • Complement System Proteins (immunology)
  • Humans
  • Immunoglobulin G (immunology)
  • Inflammation (immunology)
  • Macaca fascicularis
  • Th17 Cells (immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: